ReviewESC heart failure2021
Time-sensitive approach in the management of acute heart failure.
Review in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.ESC heart failure · 2022Trial
- Prompted Text-Based Vital Sign Recording Versus Unprompted Electronic Medical Record Entries in Patients With Advanced Heart Failure: Observational Study.JMIR formative research · 2026Observational
- Congestion-Perfusion Phenotypes and In-Hospital Mortality in Acute Heart Failure: Phenotype-Specific Prognostic Markers and Right-Heart Involvement.Medicina (Kaunas, Lithuania) · 2026Observational
- Mouse model for sensitivity of fluid measurement with textile electrodes.Biomedical engineering online · 2026Article
- Early left heart decompression protects the lungs in a canine model of acute left heart failure being treated with venoarterial extracorporeal membrane oxygenation.Frontiers in cardiovascular medicine · 2025Article
- Time to intravenous diuretic administration in patients hospitalized with heart failure: An observational study.ESC heart failure · 2024Observational
- The Management of Cardiogenic Shock From Diagnosis to Devices: A Narrative Review.CHEST critical care · 2024Article
- Endothelial Dysfunction in Heart Failure: What Is Its Role?Journal of clinical medicine · 2024Review
- Mechanical circulatory support in cardiogenic shock.Journal of intensive care · 2023Review
- Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.ESC heart failure · 2023Observational
- Acute heart failure: differential diagnosis and treatment.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Article
- Real-World Intravenous Diuretic Use to Treat Congestion in Patients With Heart Failure - An Observational Study Using a Research Database.Circulation reports · 2023Article
- Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.Clinical cardiology · 2022Review
- Evidence Based Management of Acute Heart Failure in the Era of COVID-19 Pandemic.Intensive care research · 2022Review
- Time-sensitive approach in the management of acute heart failure.ESC heart failure · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute heart failure (AHF) has become a global public health burden largely because of the associated high morbidity, mortality, and cost. The treatment options for AHF have remained relatively unchanged over the past decades. Historically, clinical congestion alone has been considered the main target for treatment of acute decompensation in patients with AHF; however, this is an oversimplification of the complex pathophysiology. Within the similar clinical presentation of congestion, significant differences in pathophysiological mechanisms exist between the fluid accumulation and redistribution. Tissue hypoperfusion is another vital characteristic of AHF and should be promptly treated with appropriate interventions. In addition, recent clinical trials of novel therapeutic strategies have shown that heart failure management is 'time sensitive' and suggested that treatment selection based on individual aetiologies, triggers, and risk factor profiles could lead to better outcomes. In this review, we aim to describe the specifics of the 'time-sensitive' approach by the clinical phenotypes, for example, pulmonary/systemic congestion and tissue hypoperfusion, wherein patients are classified based on pathophysiological conditions. This mechanistic classification, in parallel with the comprehensive risk assessment, has become a cornerstone in the management of patients with AHF and thus supports effective decision making by clinicians. We will also highlight how therapeutic modalities should be individualized according to each clinical phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.